经天宇, 刘海娇, & 刘朝一. (2022). 重组人血小板生成素注射液和艾曲泊帕乙醇胺片二线治疗原发免疫性血小板减少症的成本-效用分析. 中国药房, 33(9), 1109-1114. https://doi.org/10.6039/j.issn.1001-0408.2022.09.14
Chicago Style (17th ed.) Citation经天宇, 刘海娇, and 刘朝一. "重组人血小板生成素注射液和艾曲泊帕乙醇胺片二线治疗原发免疫性血小板减少症的成本-效用分析." 中国药房 33, no. 9 (2022): 1109-1114. https://doi.org/10.6039/j.issn.1001-0408.2022.09.14.
MLA (9th ed.) Citation经天宇, et al. "重组人血小板生成素注射液和艾曲泊帕乙醇胺片二线治疗原发免疫性血小板减少症的成本-效用分析." 中国药房, vol. 33, no. 9, 2022, pp. 1109-1114, https://doi.org/10.6039/j.issn.1001-0408.2022.09.14.
Warning: These citations may not always be 100% accurate.